Chronic kidney disease Urological and Genital Diseases Chronic kidney disease
Conditions
Interventions
In all enrolled patients we tested the effect on serum hepcidin-25 and on serum levels of a panel of biomarkers of inflammation (TNF-alfa, IL-6, Pentraxin3 and C reactive protein) of single session of
Sponsors
Azienda Ospedaliera Universitaria Integrata Verona
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged over 18 years. 2. Chronic hemodialysys patients on erytrhopoiesis-stimulating agents 3. Have been attending the unit for dialysis for more than 3 months by June 2009 4. Have participated in the previous study (protocol # 1460)
Exclusion criteria
Exclusion criteria: 1. Liver cirrhosis 2. Neoplasia 3. Chronic Inflammatory disorder 4. Acute inflammatory disease 5. Solid organ transplantation 6. No informed consent to trial # 1460
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction Ratios (RR) of hepcidin and the inflammatory biomarkers (IL-6, TNF-a, Pentraxin 3 and C-reactive protein) are calculated using the formula RR = (Cpre - Cpost/Cpre) x 100 (where Cpre is the concentration just before dialysis and Cpost the concentration at the end of dialysis). | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood-side clearance of hepcidin and the inflammatory biomarkers (IL-6, TNF-a, Pentraxin 3 and C-reactive protein) calculated 90 minutes after the dialysis starts. Blood samples for the assays were taken from the dialyzer inlet and outlet:. K was calculated by the formula K= Qb x (Cbi –Cbo / Cbi), where Qb is the blood flow rate, Cbi is the solute serum levels at the dialyzer inlet, and Cbo the solute serum levels at the dialyzer outlet. | — |
Countries
Italy
Outcome results
None listed